Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation

Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation Publisher Pubmed

Madani F¹ ; Esnaashari SS² ; Bergonzi MC³ ; Webster TJ⁴ ; Younes HM⁵ ; Khosravani M¹ ; Adabi M¹

Show Affiliations

1. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
3. Department of Chemistry, University of Florence, Via U. Schiff 6, Sesto Fiorentino, Florence, 50019, Italy
4. Chemical Engineering Department, Northeastern University, Boston, 02115, MA, United States
5. Office of Vice President For Research & Graduate Studies, Qatar University, Doha, Qatar

Source: Life Sciences Published:2020

Abstract

Aim: The aim of this study was to improve the therapeutic index of chemotherapeutic drugs on glioblastoma cells through an improved co-drug delivery system. Materials and methods: Methotrexate (MTX) and paclitaxel (PTX) were co-loaded into poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) coated with polyvinyl alcohol (PVA) and Poloxamer188 (P188). Key findings: The mean size of the NPs was about 212 nm, with a zeta potential of about −15.7 mV. Encapsulation efficiency (EE%) and drug loading (DL%) were determined to be 72% and 4% for MTX and 85% and 4.9% for PTX, respectively. The prepared NPs were characterized by differential thermal analysis (DTA) and thermogravimetric analysis (TGA). Moreover, an in vitro sustained release profile was observed for both drug loaded PLGA NPs. Glioblastoma cellular uptake of the NPs was confirmed by fluorescence microscopy and cell survival rate was investigated through the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method after 48 h of incubation showing IC50 values of 24.5 μg·mL−1 for PTX and 9.5 μg·mL−1 for MTX for the MTX/PTX co-loaded PLGA nanoparticles coated with PVA/P188 (Co-2 NPs). Apoptosis and necrosis were also studied via flow cytometry, the lactate dehydrogenase (LDH) assay and the amount of anti-apoptotic protein (Bcl-2) expression. Blood compatibility of the co-delivery of PTX and MTX loaded PLGA NPs was investigated using a hemolysis method as well. Significance: The co-delivery of PTX and MTX loaded PLGA NPs is promising for the treatment of glioblastoma compared to their respective free drug formulations and, thus, should be further investigated. © 2020

Related Docs

View other Related Docs

1. Combination Nanochemotherapy of Brain Tumor Using Polymeric Nanoparticles Loaded With Doxorubicin and Paclitaxel: An in Vitro and in Vivo Study, European Journal of Pharmaceutics and Biopharmaceutics (2023)

2. Combination Chemotherapy Via Poloxamer 188 Surface-Modified Plga Nanoparticles That Traverse the Blood–Brain–Barrier in a Glioblastoma Model, Scientific Reports (2024)

3. Glyco-Nanoparticles: New Drug Delivery Systems in Cancer Therapy, Seminars in Cancer Biology (2021)

4. Preparation of Methotrexate Loaded Plga Nanoparticles Coated With Pva and Poloxamer188, Nanomedicine Research Journal (2018)

5. Preparation of Paclitaxel and Etoposide Co-Loaded Mpeg-Plga Nanoparticles: An Investigation With Artificial Neural Network, Journal of Pharmaceutical Innovation (2021)

6. Investigation of Effective Parameters on Size of Paclitaxel Loaded Plga Nanoparticles, Advanced Pharmaceutical Bulletin (2018)

7. Specific Cellular Internalization and Ph-Responsive Behavior of Doxorubicin Loaded Plga-Peg Nanoparticles Targeted With Anti Egfrviii Antibody, Life Sciences (2020)

8. Polymeric Nanoparticles for Drug Delivery in Glioblastoma: State of the Art and Future Perspectives, Journal of Controlled Release (2022)

Experts (# of related papers)

View all Related Experts

Masood Khosravani (12)

Mahdi Adabi (12)

Style	Citing Format
MLA	Madani F, et al.. "Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation." Life Sciences, vol. 256, no. , 2020, pp. -.
APA	Madani F, Esnaashari SS, Bergonzi MC, Webster TJ, Younes HM, Khosravani M, Adabi M (2020). Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation. Life Sciences, 256(), -.
Chicago	Madani F, Esnaashari SS, Bergonzi MC, Webster TJ, Younes HM, Khosravani M, Adabi M. "Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation." Life Sciences 256, no. (2020): -.
Harvard	Madani F et al. (2020) 'Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation', Life Sciences, 256(), pp. -.
Vancouver	Madani F, Esnaashari SS, Bergonzi MC, Webster TJ, Younes HM, Khosravani M, et al.. Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation. Life Sciences. 2020;256():-.
BibTex	@article{ author = {Madani F and Esnaashari SS and Bergonzi MC and Webster TJ and Younes HM and Khosravani M and Adabi M}, title = {Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation}, journal = {Life Sciences}, volume = {256}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Madani F AU - Esnaashari SS AU - Bergonzi MC AU - Webster TJ AU - Younes HM AU - Khosravani M AU - Adabi M TI - Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation JO - Life Sciences VL - 256 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract